If you don't remember your password, you can reset it by entering your email address and clicking the Reset Password button. You will then receive an email that contains a secure link for resetting your password
If the address matches a valid account an email will be sent to __email__ with instructions for resetting your password
Department of Pathology, Graduate School of Medicine, the University of Tokyo, Tokyo, JapanDepartment of Craniofacial Development and Orthodontics, King's College London, Guy's Hospital, London, United Kingdom
Podoplanin is a type-I transmembrane sialomucin-like protein, which is expressed in a wide range of cell types and is involved in platelet aggregation and tumor metastasis. Here, we investigated the function, regulation, and expression of podoplanin in osteosarcoma. Podoplanin expression was observed in three osteosarcoma cell lines (MG-63, HOS, and U-2 OS) with platelet aggregation–inducing ability, which was blocked by podoplanin small-interfering RNA or a neutralizing antibody. Overexpression of podoplanin in nonmetastatic Dunn osteosarcoma cells promoted cell migration without attenuating cell proliferation. Both podoplanin and TGF-β1 were up-regulated by c-Fos induction in MC3T3-E1 osteoblastic cells, and were highly expressed in c-Fos transgenic mouse osteosarcomas and c-Fos–transformed osteosarcoma cell lines. Immunohistochemistry of human osteosarcoma tissue microarrays (n = 133) showed staining of tumor cells embedded in an excess of irregular neoplastic bone matrix in 100% of tumors undergoing so-called “normalization/maturation.” Podoplanin was also expressed in osteosarcoma subtypes, with 65% of osteoblastic, 100% of chondroblastic, and 79% of fibroblastic tumors. CD44 and pERM immunohistochemistry showed coexpression with podoplanin in both mouse and human osteosarcoma. Podoplanin expression was significantly higher in metastatic osteosarcomas (n = 6) than in primary osteosarcomas (n = 10). Our data suggest that podoplanin, which is not expressed in normal osteoblasts but in osteocytes, is aberrantly expressed in transformed osteoblasts and in osteosarcoma, and is under AP-1 transcriptional control. Thus podoplanin is a candidate molecule for therapeutic targeting.
Osteosarcoma (OS) is the most common primary malignant bone tumor, with a high tendency to metastasize to the lung. Despite recent advances in modern chemotherapy, the average survival after a recurrence in distant organs is less than 1 year.
Therefore, there is a strong necessity to better understand the molecular mechanisms of metastasis to deliver innovative life-saving and life-enhancing therapies to patients.
Platelet aggregation is one of the crucial steps involved during the sequential tumor metastasis process to escape from the host immune system and form tumor emboli in distant organs. Several earlier studies have shown that platelet aggregating capability of tumor cells from colon cancer and melanoma is correlated with their metastatic potential in vivo.
podoplanin is expressed exclusively by osteocytes, especially newly formed and young osteocytes (osteoid osteocytes). Gain- and loss-of-function studies have demonstrated that podoplanin plays a functional role in the formation of osteocyte dendritic processes.
Several growth factors, including epidermal growth factor (EGF), basic fibroblast growth factor (FGF2), and transforming growth factor-β (TGF-β), are known to induce podoplanin expression in MCF7 breast cancer cells.
Extensive work using gain- and loss-of-function analyses in mice have established an important role for c-Fos in proliferation and differentiation of normal cells, but also in cellular transformation and tumor formation.
Although the role of podoplanin in platelet aggregation, cell migration, and metastasis of carcinoma cells is established, there has been one previous report in human OS cell lines suggesting that their ability to induce platelet aggregation in vitro might relate to their ability to metastasize.
We therefore postulated that podoplanin expression would be expressed in human OS in vivo and involved in OS metastasis. To this end, we investigated the role of podoplanin on their platelet aggregation inducing activity as well as cell migration capacity in OS cells. Further, as a c-Fos target gene, we investigated the expression of podoplanin in c-Fos–inducible osteoblastic cell lines
Finally, we carried out detailed expression analysis of podoplanin in a number of human OS. Our results indicated a potential use of podoplanin for therapeutic aims.
Materials and Methods
Cell Culture and Establishing Stable Podoplanin Overexpressing OS Cells
The mouse OS cell line Dunn (a kind gift from Dr. Takafumi Ueda, Osaka University, Japan), the human OS cell lines (all obtained from American Type Culture Collection, Manassas, VA), MG-63, HOS, and U-2 OS, and the mouse OS cell lines P1.7, P1.9, and P1.15, derived from bone tumors formed in c-Fos–overexpressing transgenic mice, were cultured under standard conditions.
The tetracycline-regulatable, c-Fos–overexpressing MC3T3-E1 mouse osteoblastic cell subclone, AT9.2, was cultured in the presence of tetracycline, and exogenous c-Fos expression was induced following withdrawal of tetracycline (Tet-off system).
Normal human primary osteoblasts were purchased (Lonza, Basel, Switzerland) and used within a few passages. For establishment of stable podoplanin-overexpressing cells, transfection of pcDNA3-human podoplanin cDNA
and a control pcDNA3 vector into Dunn cells was performed using LipofectAMINE 2000 reagent (Invitrogen, Carlsbad, CA), and the colonies showing resistance to G418 were isolated.
Human Tissue Specimens
We analyzed a series of primary OS (n = 100) and pulmonary metastases (n = 33) using tissue microarrays (TMAs) as well as four normal human bone sections. The samples were routinely fixed in 10% formalin, decalcified, then embedded in paraffin. TMA blocks were constructed by using a manual tissue arrayer (Beecher Instrument, Sun Prairie, WI) using duplicated 2-mm cores for each case (n = 83). In addition, we also used a commercial OS TMA containing 50 single 1-mm cores from human OS (OS801; US Biomax, Rockville, MD).
First-strand cDNA samples were prepared from 0.5 μg of total RNA as previously described.
were examined by immunohistochemistry and in situ hybridization. Five-week-old BALB/c mice (Charles River Japan Inc., Kanagawa, Japan) were used for platelet aggregation assays. To generate xenograft samples, 106 of P1.15 cells were subcutaneously injected into the back of nude mice (Charles River Japan Inc., Kanagawa, Japan), and the mice were sacrificed after 4 weeks (n = 4). The Animal Care and Use Committee and the Ethics Committee of the University of Tokyo approved the animal experiments described herein (1822T-020).
Western Blot Analysis
Total protein extracts from cultured cells and tissues were prepared and separated using SDS-PAGE and blotted as previously described.
or an anti–β-actin antibody (Sigma, St. Louis, MO), followed by a horseradish peroxidase–conjugated secondary antibody, and developed using the ECL system (GE Healthcare, Chalfont St. Giles, Buckinghamshire, England, UK).
Small-interfering RNA (siRNA) oligos, designed for specific podoplanin knockdown (hPDPN siRNA-sense: 5′-GUCUGGCUUGACAACUCUGTT-3′; hPDPN siRNA-antisense: 3′-CAGAGUUGUCAAGCCAGACTT-5′), were transiently introduced using LipofectAMINE 2000 reagent. As a negative control, we used a nonsilencing control siRNA. Cells were used for in vitro experiments 24 hours after siRNA transfection.
Cell Migration Assay
Cell migration assays were performed using transwell inserts (8 μm pore size; Corning, NY), and the number of cells that migrated was counted after 18 hours as previously described.
For antibody neutralization, 50 μg/mL of anti-human podoplanin antibody (NZ-1) or control normal rat IgG were mixed with cells, then incubated for 15 minutes on ice before seeding onto a transwell. All experiments were performed in triplicate.
In Vitro Cell Proliferation Assay
In vitro growth of stable transfectants was assessed using a Cell Counting Kit-8 (Dojin Laboratories, Kumamoto, Japan); the optical density was measured using a microplate reader (Model 550; Bio-Rad, Hercules, CA). To examine the three-dimensional proliferation of stable clones, 103 cells were seeded into a round-bottom 96-well plate (Sumilon Celltight Spheroid; Sumilon, Tokyo, Japan), and the mean diameters of the spheroids were measured every other day for 12 days as described previously.
Platelet aggregation was quantified by light transmittance using an MCM HEMA Tracer 313M (MC Medical, Tokyo, Japan). Platelet-rich plasma was prepared from fresh, heparinized blood that was drawn from BALB/c mice by cardiac puncture and then centrifuged (170 × g, 15 minutes) at 23°C. Platelet-poor plasma was obtained by centrifugation (1500 × g, 10 minutes) of the remaining blood at 23°C. Platelet-rich plasma was preincubated for 5 minutes at 37°C, with constant stirring in the aggregometer. Platelet aggregation was then initiated by the addition of tumor cells (1 × 106 cells/mL) and monitored as an extent of light transmittance to platelet-poor plasma. Alternatively, platelet aggregation was initiated by adding tumor cells (5 × 106 cells/sample) and determined by measuring electric impedance,
using a whole-blood aggregometer Model 560 (Chronolog, Havertown, PA).
Semiquantitative RT-PCR and Quantitative Real-Time PCR
The primers used in this study were followings: Mouse podoplanin (sense 5′-CTCAAGCTTCAAGATGTGGACCGTGCCAGT-3′, antisense 5′-GAGGAATTCGGGCGAGAACCTTCCAGAAAT-′3), Mouse c-Fos (sense 5′-GCTGACAGATACACTCCAAGCGG-3′, antisense 5′-AGGAAGACGTGTAAGTAGTGCAG-3′), Mouse Tgfβ1 (sense 5′-GACTCTCCACCTGCAAGACCA-3′, antisense 5′-GGGACTGGCAGCCTTAGTT-3′), Mouse β-actin (sense 5′-GATATCGCTGCGCTGGTCGTCGAC-3′, antisense 5′-CAAGAAGGAAGGCTGGAAAAGAGC-3′), Human podoplanin (sense 5′-GGAAGGTGTCAGCTCTGCTC-3′, antisense 5′-CGCCTTCCAAACCTGTAGTC-3′) and Human β-actin (sense 5′-ACTCTTCCAGCCTTCCTTCCTG-3′, antisense 5′-ATCTCCTTCTGCATCCTGTCGG-3′). The first-strand cDNA were amplified by PCR, and real-time PCR was performed using QuantiTect SYBR Green PCR (Qiagen, Valencia, CA). Standard curves for templates of podoplanin and an endogenous control, β-actin, were generated by serial dilution of the PCR products (1 × 108 to 1 × 103 copies/mL).
Immunohistochemistry and in Situ Hybridization
Sections were incubated with the following antibodies: anti-human podoplanin (NZ-1), anti-mouse podoplanin (RDI, Concord, MA), anti-human CD44 (GeneTex, Inc., Irvine, CA), anti-mouse CD44 (IM7; BD Pharmigen, Oxford, UK), anti-phospho-Ezrin (Thr567)/Radixin (Thr564)/Moesin (Thr558) (Cell Signaling Technology Inc., Danvers, MA), anti–c-Fos (sc-52; Santa Cruz Biotechnology, Santa Cruz, CA), or anti-TGF-β1 (sc-146; Santa Cruz Biotechnology). Sections for all of the antibodies, except NZ-1, were pre-treated using the microwave antigen retrieval method. After applying a biotin-conjugated secondary antibody, immunoreactivity was visualized using Vectastain ABC Kit (Vector Laboratories, Peterborough, UK). Assessment of immunohistochemistry was performed as described in Table 1. For detection of mouse Tgf-β1, a KpnI-ApaI–digested fragment of the cDNA (approximately 600 bp, accession number: M13177) was labeled by 35S using in vitro transcription and in situ hybridization was carried out as described previously.
Table 1Summary of Podoplanin Immunostaining of Human OS
Primary tumors (n = 100)
Normalization/maturation (n = 51/100)
Osteoblastic (n = 65/100)
Chondroblastic (n = 15/100)
Fibroblastic (n = 20/100)
Metastatic tumors (n = 33)
Normalization/maturation (n = 15/33)
Osteoblastic (n = 15/33)
Chondroblastic (n = 4/33)
Fibroblastic (n = 14/33)
A total of 133 osteosarcoma (OS) TMA samples (comprising 83 duplicated institutional and 50 single commercial cores) were examined by immunohistochemistry. Duplicated cores counted as one case. OS showing normalization/maturation
were assessed for podoplanin expression at neoplastic dendritic processes. Membranous staining was also evaluated in each core, according to the conventional OS subtypes, osteoblastic, chondroblastic, and fibroblastic OS. Immunohistochemistry staining of TMA cores was evaluated semi-quantitatively based on number of positive tumor cells as follows: ++, >50% of tumor cells; +, <50% of tumor cells; −, negative.
All data sets were analyzed using Graphpad Prism v.4 (Graphpad Software Inc., San Diego, CA) and shown as means ± SEM. Mann-Whitney U-test, or one-way analysis of variance followed by Tukey-Kramer multiple comparisons was performed, where appropriate. P values < 0.05 were considered statistically significant. All statistical tests were two-tailed.
The Role of Podoplanin in Platelet Aggregation in OS Cell Lines
We first addressed the function of podoplanin in OS by examining its ability to induce platelet aggregation. Three human OS cell lines, MG-63, HOS, and U-2 OS expressed high levels of endogenous podoplanin as examined by Western blotting (Figure 1A) and flow cytometry (see Supplemental Figure S1 at http://ajp.amjpathol.org). Incubation with platelet-rich plasma showed that podoplanin was functional, because all three OS cells were capable of inducing platelet aggregation (Figure 1B). To further confirm whether this platelet aggregation–inducing ability was depending on podoplanin, we knocked down podoplanin expression using a specific podoplanin siRNA, and Western blot analysis confirmed an 85% reduction in protein expression levels (Figure 1C). This resulted in a prolonged incubation period for stimulating platelet aggregation, suggesting a reduction in aggregating activity (Figure 1D). These observations indicate that podoplanin functions as a platelet aggregation–inducing factor in OS cells.
Next, we investigated the consequences of ectopic podoplanin expression using the mouse Dunn OS cell line that shows no endogenous expression of podoplanin protein. Three stable podoplanin-expressing clones (PDPN-11, -14, and -17) were used in further experiments. As shown in Figure 2A, Western blot analysis confirmed the expression level of exogenous podoplanin, where the expression level was the highest in PDPN-17, and PDPN-11 had the lowest expression. Cell surface expression of podoplanin was also confirmed by flow cytometry. We next investigated whether podoplanin overexpression promoted platelet aggregation in the transfectants. After 20 minutes, all of the podoplanin-expressing OS cells showed enhanced platelet aggregation–inducing activity, with the highest activity in PDPN-17 and the lowest in PDPN-11, corresponding to the exogenous podoplanin protein levels (Figure 2B), whereas the control mock-transfectant did not show platelet aggregation even after 1 hour (data not shown). Analysis of the growth rates of podoplanin-expressing clones demonstrated that they were not significantly different from that of the control cells in monolayer culture (Figure 2C). Likewise, three-dimensional spheroid growth did not show any differences in growth (Figure 2D). These findings further confirm that podoplanin functions as a platelet aggregation–inducing factor in OS cells but does not affect cell growth.
Podoplanin Promotes OS Cell Migration
To evaluate whether podoplanin overexpression causes altered migration behavior of OS cells, we used an in vitro migration assay. The transfectants showed a higher migration rate than mock cells; the migrated cell numbers of PDPN-17 and PDPN-14 were sixfold (P < 0.001) and threefold (P < 0.001) greater than that of mock cells, respectively, which was again proportional to the exogenous podoplanin levels (Figure 3A). PDPN-11, with the lowest expression level of exogenous podoplanin, showed an increase in migration, yet there was no statistical difference. To further confirm the increase in the motility of podoplanin-expressing cells, we tested whether or not blocking podoplanin function had any effect on motility. As shown in Figure 4B, U-2 OS cells neutralized with an anti-podoplanin antibody exhibited a significantly decreased migration, in comparison to the IgG-treated cells (108 ± 33 versus 34 ± 11, P = 0.0022). These results indicate that podoplanin expression plays an important functional role in the migration of OS cells.
c-Fos Up-Regulates Podoplanin Expression in Transformed Osteoblasts
Since overexpression of c-Fos in transgenic mice results in the formation of OS,
we next investigated its relevance to podoplanin expression in OS. First, we investigated whether exogenous c-Fos affected the expression of podoplanin using a subclone of murine MC3T3-E1 osteoblastic cells, AT9.2, which expresses c-Fos in a tetracycline (Tet)-regulatable manner (Tet-off system).
AT9.2 cells were cultured in the presence or the absence of Tet, and then semiquantitative RT-PCR analysis was performed to examine the expression of c-Fos, podoplanin, and an additional c-Fos target, TGF-β1. Induction of exogenous c-Fos resulted in the stimulation of podoplanin expression as well as TGF-β1 expression (Figure 4A). We then investigated podoplanin expression in the c-Fos transgenic OS-derived cell lines, P1.7, P1.9, and P1.15.
Podoplanin was expressed in all of the cell lines, albeit at different levels, as shown by Western blot analysis (Figure 4B). Moreover, subcutaneous tumor xenografts of these cells showed intense membranous podoplanin expression in elongated cells as well as in plump, cuboidal cells showing osteocartilagenous differentiation (Figure 4C). In addition, immunohistochemistry of tumor cells for CD44 and phosphorylated ERM (pERM) showed cell surface staining (Figure 4, D–G).
To clarify in greater detail the cell types expressing podoplanin in vivo, immunohistochemistry was performed in normal mouse bone and c-Fos transgenic OS. In normal bone, podoplanin expression was observed in bone-forming cells including osteocytes and osteoid osteocytes at their dendritic processes within canaliculi, as well as in very few mature bone-forming osteoblasts (only a few cells in an entire section) and periosteal cells (see Supplemental Figure S2 at http://ajp.amjpathol.org). In c-Fos transgenic mouse OS, osteoblastic tumor cells that were adjacent to bone matrix, as well as osteocyte-like tumor cells with irregular dendritic processes, showed high levels of podoplanin staining (Figure 4H). All of the tumor cells were confirmed to express c-Fos protein (Figure 4I). Moreover, high levels of TGF-β1 protein and mRNA expression were observed in osteoblastic areas of c-Fos transgenic OS (Figure 4, J and K; see also Supplemental Figure S3 at http://ajp.amjpathol.org).
Expression of Podoplanin in Human OS Tissues
We carried out immunohistochemical analysis on normal bone and on OS TMA samples. In normal bone, osteoid osteocytes with abundant cytoplasm showed intense membrane immunoreactivity using a podoplanin antibody, notably at the spiky, urchin-like dendritic processes in the canaliculi, whereas mature osteocytes and surface-lining osteoblasts expressed little to no podoplanin (Figure 5A). We examined a total of 133 OS TMA samples, comprising 100 primary tumors and 33 metastatic lesions. Two distinct staining patterns were observed: First, in tumors that were undergoing so-called “normalization” or “maturation”,
tumor cells that were embedded in the excess of irregular neoplastic bone matrix showed an intense podoplanin staining pattern in the disorganized dendritic-like processes that was similar to osteoid osteocytes and c-Fos transgenic OS (Figure 5B). This was observed in 100% of cores from 51 primary and 15 metastatic tumors that were undergoing normalization (Table 1). Second, strong cell surface podoplanin staining was observed in pleomorphic and rounded tumor cells present in less differentiated tumors (Figure 5C). Interestingly, this was reminiscent of the expression pattern in c-Fos transgenic OS cell xenografts (Figure 4C). We next evaluated podoplanin expression across the different OS subtypes in both primary and metastatic tumors. From 80 osteoblastic OS (eg, Figure 5D), 65% (52 of 80) showed membranous podoplanin staining, whereas 100% (19 of 19) of chondroblastic OS (eg, Figure 5E) and 79% (27 of 34) fibroblastic OS (eg, Figure 5F) expressed podoplanin at the cell membrane. Taken together, these results demonstrate high podoplanin expression in the majority of human OS. In fact, there was an overall tendency toward metastatic OS samples expressing podoplanin at higher frequency than primary tumor samples, representing 87.9% (29 of 33 cores) versus 69% (69 of 100 cores), respectively. Finally, similarly to the mouse OS xenografts, immunolocalization studies showed cell surface expression of CD44 and pERM in human OS (Figure 5, G–J).
To further quantify and confirm podoplanin expression in human primary and metastatic OS, we performed real-time quantitative PCR studies and showed that the expression level of podoplanin mRNA in metastatic tumors was two- to threefold higher than in primary tumors (P = 0.0312, Figure 6A). Since the metastatic tumor samples also contained lung tissue, where type I alveolar cells are also known to express podoplanin,
we examined podoplanin protein expression in normal lung tissue and normal primary osteoblasts for comparison. The data confirmed that the contribution of podoplanin expression from lung tissue was minimal (Figure 6B). Although we cannot rule out that lung tissue itself might induce podoplanin expression in the metastatic OS cells, our data suggest that the high expression levels of podoplanin protein in OS metastatic samples are largely due to OS-derived podoplanin.
In the current study, we have investigated the function and regulation of podoplanin in OS cells and have characterized its detailed expression pattern in both human OS as well as in c-Fos–induced OS in transgenic mice. We originally identified podoplanin as the platelet aggregation factor Aggrus,
In the present study, we have extended these observations to OS, which show a high propensity to form lung metastases, and showed that podoplanin was expressed in three different human OS cell lines, which correlated with their ability to induce platelet aggregation. Indeed, functional studies showed that the platelet aggregation–inducing capacity was reduced by knockdown of endogenous podoplanin in human OS cells, and conversely, was promoted by overexpressing podoplanin in the nonmetastatic Dunn mouse OS cell line. Taken together, these results suggested that podoplanin plays an important functional role in a platelet aggregation during the process of OS metastasis.
Podoplanin was found previously to induce cell migration by modulating the actin cytoskeleton.
In the present study, knockdown of endogenous podoplanin using siRNA resulted in reduced cell migration in OS cells. Moreover, a neutralizing anti-podoplanin antibody, which dramatically reduced tumor metastasis in our previous study,
significantly reduced the motility of U-2 OS cells. One essential step in the sequences required for cell migration is filopodia formation mediated by Ezrin, a member of ERM (Ezrin-Radixin-Moesin) cytoskeleton-associated protein family,
and our study showed that podoplanin expression levels in metastatic OS were higher than in primary OS. As we have shown coexpression of podoplanin/CD44/pERM, it is tempting to speculate that such a complex plays a role in the underlying mechanisms of cell migration and in further establishing metastasis in OS.
Podoplanin was up-regulated by the induction of the AP-1 oncoprotein, c-Fos, in mouse osteoblastic cells, which is consistent with the high expression of podoplanin in c-Fos–transformed OS and its derived OS cells. c-Fos is highly expressed in the vast majority of human OS
was highly expressed in c-Fos transgenic mouse OS at both the mRNA and protein levels. Furthermore, nontransformed, c-Fos–overexpressing mouse osteoblasts showed high levels of podoplanin and TGF-β1 expression in a c-Fos–dependent manner. Taken together, both c-Fos and TGF-β1 appear to act in concert and are very likely responsible for the high levels of podoplanin expression observed in c-Fos transgenic OS and human OS. These high podoplanin levels are an important observation because podoplanin expression is normally very tightly regulated and is expressed by only a few normal osteoblasts with no dendritic processes that are destined to become osteocytes.
Thus, on the basis of the data presented here, we would suggest that the highly deregulated expression of podoplanin in OS contributes to OS tumor progression and metastasis.
In this study, we showed that podoplanin is expressed in more than two-thirds of conventional OS TMA samples. Consistent with our mRNA and immunoblot protein expression data, our immunohistochemical analysis of human OS revealed high expression of podoplanin in immature tumor cells with cell membrane localization, yet the number of positive lesional cells varied, presumably due to tumor heterogeneity and TMA core sampling variations. Meanwhile, virtually all of the tumor cells showing “normalization” or “maturation,” which are characterized as a differentiation toward mature osteocyte-like cells in excessive bone matrix,
expressed podoplanin at disorganized dendritic processes. These apparently paradoxical observations, that both immature and differentiating tumor cells express podoplanin, suggest that there is a podoplanin-positive immature subpopulation, which represents aggressive tumor cells, similar to the previously reported subpopulation of podoplanin-positive cells in the A431 human epidermoid carcinoma cell line.
Moreover, whereas c-Fos transgenic OS in vivo rarely showed strong specific membranous podoplanin antibody labeling, c-Fos transgenic OS–derived cell lines and their resulting tumor xenografts showed an intensive membranous podoplanin immunostaining. This further supports our notion that the normally tight control of podoplanin expression in normal bone appears to be lost in immature tumor cells.
Although podoplanin is a well-characterized osteocyte marker, its expression and function in bone neoplasms is not well understood.
OS are known to express aberrantly a wide range of osteoblast differentiation markers, including transcription factors, serum enzymes such as alkaline phosphatase, noncollagenous bone proteins, and cell surface antigens.
As tumor cells in OS are generally regarded as being immature, previous studies have focused typically on analyzing marker genes of early osteoblast differentiation, rather than late stage and fully differentiated osteoblast phenotypes. Thus, the elucidation of podoplanin expression across a wide range of different OS is important. We are currently continuing to investigate aberrant bone cell marker gene expression during the osteoblast differentiation program in different bone tumors including OS, which would be essential for understanding the pathobiology and for contributing further to an accurate histopathological diagnosis and a clinical management of bone tumors.
In conclusion, we have shown that podoplanin expression is under AP-1 control in osteoblasts and plays a crucial role in enhancing platelet aggregation and cell migration of OS. Thus, podoplanin and its regulator c-Fos could be a potential new therapeutic target in OS patients for preventing OS metastasis by attenuating cell migration as well as platelet aggregation.
We thank Dr. Takashi Nishiyama, Arisa Ogiwara, and Harumi Yamamura for their technical assistance; Prof. Gerhard Christofori (University of Basel, Switzerland) for critically reading the manuscript; and Prof. Nicolas A. Athanasou (University of Oxford, UK) for helpful discussions.
Flow cytometric analysis of podoplanin expression. Flow cytometric analysis confirmed the cell surface expression of podoplanin in human osteosarcoma cell lines. Cells were treated with an anti-podoplanin antibody following incubation with Oregon Green 488-conjugated secondary antibody.
Immunohistochemistry of podoplanin in normal mouse bone. A: Intense podoplanin staining in young osteoid osteocytes and in osteocyte processes in canaliculi connected to surface lining cells. B: High magnification of an osteoid osteocyte showing high podoplanin expression in the abundant cell body as well as in osteocyte processes. C: High podoplanin expression in a subpopulation of cuboidal, bone-forming osteoblasts with a plump cytoplasm (arrows). Expression levels are similar to young osteocytes. D: Mature osteocytes and periosteal osteogenic/fibroblastic cells (arrows) showed weak immunoreactivity to the podoplanin antibody.
Radioactive ISH analysis of Tgfβ1 in c-Fos transgenic OS. Bright-field (A) and dark-field (B) microphotographs confirming Tgfβ1 mRNA in tumour cells detected by radioactive in situ hybridisation. C: Merged images of (A) and (B). The dark-field images were inverted, the colour was artificially transformed to red, then merged with the bright-field image using Adobe Photoshop. Scale bars = 50 μm.
Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS).
Supported in part by a grant for Research Fellowships from the Japanese Society for the Promotion of Science for Young Scientists, Japan (A.K.), a grant (no 16790202 to T.G.K.) from the Ministry of Education, Culture, Sports, Science & Technology, and a grant from the UK Bone Cancer Research Trust (No. 09/08 to A.E.G.).
Supplemental material for this manuscript can be found at http://ajp.amjpathol.org or at doi: 10.1016/j.ajpath.2011.04.027.
Current address of A.O., Department of Craniofacial Development, King's College London, Guy's Hospital, London, United Kingdom.